These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 27886573)
21. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Verras M; Lee J; Xue H; Li TH; Wang Y; Sun Z Cancer Res; 2007 Feb; 67(3):967-75. PubMed ID: 17283128 [TBL] [Abstract][Full Text] [Related]
22. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741 [TBL] [Abstract][Full Text] [Related]
23. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Bonaccorsi L; Carloni V; Muratori M; Formigli L; Zecchi S; Forti G; Baldi E Int J Cancer; 2004 Oct; 112(1):78-86. PubMed ID: 15305378 [TBL] [Abstract][Full Text] [Related]
24. Plexin-B1 signalling promotes androgen receptor translocation to the nucleus. Williamson M; de Winter P; Masters JR Oncogene; 2016 Feb; 35(8):1066-72. PubMed ID: 25982277 [TBL] [Abstract][Full Text] [Related]
25. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561 [TBL] [Abstract][Full Text] [Related]
26. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Shiota M; Yokomizo A; Masubuchi D; Tada Y; Inokuchi J; Eto M; Uchiumi T; Fujimoto N; Naito S Prostate; 2010 Apr; 70(5):540-54. PubMed ID: 19938016 [TBL] [Abstract][Full Text] [Related]
27. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959 [TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Lin DL; Whitney MC; Yao Z; Keller ET Clin Cancer Res; 2001 Jun; 7(6):1773-81. PubMed ID: 11410519 [TBL] [Abstract][Full Text] [Related]
29. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158 [TBL] [Abstract][Full Text] [Related]
30. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Saporita AJ; Ai J; Wang Z Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841 [TBL] [Abstract][Full Text] [Related]
31. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Xie Y; Wolff DW; Lin MF; Tu Y Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995 [TBL] [Abstract][Full Text] [Related]
32. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cha TL; Qiu L; Chen CT; Wen Y; Hung MC Cancer Res; 2005 Mar; 65(6):2287-95. PubMed ID: 15781642 [TBL] [Abstract][Full Text] [Related]
33. Crosstalk between EGFR and extranuclear steroid receptors. Migliaccio A; Castoria G; Di Domenico M; Ciociola A; Lombardi M; De Falco A; Nanayakkara M; Bottero D; De Stasio R; Varricchio L; Auricchio F Ann N Y Acad Sci; 2006 Nov; 1089():194-200. PubMed ID: 17261767 [TBL] [Abstract][Full Text] [Related]
34. Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells. Koochekpour S; Lee TJ; Sun Y; Hu S; Grabowski GA; Liu Z; Garay J J Cell Biochem; 2008 Aug; 104(6):2272-85. PubMed ID: 18481277 [TBL] [Abstract][Full Text] [Related]
35. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells. Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071 [TBL] [Abstract][Full Text] [Related]
36. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555 [TBL] [Abstract][Full Text] [Related]
37. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070 [TBL] [Abstract][Full Text] [Related]
38. Cytoplasmic, full length and novel cleaved variant, TBLR1 reduces apoptosis in prostate cancer under androgen deprivation. Daniels G; Zhang X; Zhong X; Santiago L; Wang LH; Wu X; Zhang JY; Liang F; Li X; Neubert TA; Steinke L; Shen Y; Basch R; Schneider R; Levy DE; Lee P Oncotarget; 2016 Jun; 7(26):39556-39571. PubMed ID: 27127173 [TBL] [Abstract][Full Text] [Related]
39. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Heitzer MD; DeFranco DB Cancer Res; 2006 Jul; 66(14):7326-33. PubMed ID: 16849583 [TBL] [Abstract][Full Text] [Related]
40. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Sadar MD; Gleave ME Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]